Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus (Q84062748)

From Wikidata

Jump to navigation Jump to search

scientific article published on 07 May 2011

Language	Label	Description	Also known as
English	Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus	scientific article published on 07 May 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

type 2 diabetes

1 reference

based on heuristic

inferred from title

atrial fibrillation

1 reference

based on heuristic

inferred from title

catheter ablation

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21551479

1 December 2024

author name string

Jun Gu

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Xu Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Xinhua Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Haifeng Shi

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Hongwei Tan

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Li Zhou

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Jianing Gu

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Weifeng Jiang

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Yuanlong Wang

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21551479

1 December 2024

publication date

7 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1256-1261

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Personnel, Policy, Procedures and Follow-Up

1

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Atrial fibrillation: basic mechanisms, remodeling and triggers.

2

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Is atrial fibrillation an inflammatory disorder?

3

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases

4

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation

5

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Does inflammation influence atrial fibrillation recurrence following catheter ablation?

6

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation

7

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

8

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.

9

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production

10

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels

11

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Comparison of characteristics and significance of immediate versus early versus no recurrence of atrial fibrillation after catheter ablation

12

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Pulmonary vein isolation combined with superior vena cava isolation for atrial fibrillation ablation: a prospective randomized study

13

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Current concepts in the pathogenesis of atrial fibrillation

14

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Acute and chronic pulmonary vein reconnection after atrial fibrillation ablation: a prospective characterization of anatomical sites

15

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Very late relapse of atrial fibrillation after pulmonary vein isolation: incidence and results of repeat ablation

16

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation

17

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Predictors of recurrence following catheter ablation of atrial fibrillation using an irrigated-tip ablation catheter

18

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Predictors of success after selective pulmonary vein isolation of arrhythmogenic pulmonary veins for treatment of atrial fibrillation

19

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Atrial Substrate Properties and Outcome of Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation Associated With Diabetes Mellitus or Impaired Fasting Glucose

20

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

What are arrhythmogenic substrates in diabetic rat atria?

21

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study

23

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Inflammation of atrium after cardiac surgery is associated with inhomogeneity of atrial conduction and atrial fibrillation

24

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Atrial glutathione content, calcium current, and contractility

25

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

26

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study

27

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Pioglitazone improves superoxide dismutase mediated vascular reactivity in the obese Zucker rat.

28

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis

29

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial

30

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Inflammation in the genesis and perpetuation of atrial fibrillation

31

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence

32

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Histopathology of canine hearts subjected to catheter ablation using radiofrequency energy

33

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation

34

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on the Long-Term Outcome after Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation

35

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Pioglitazone-induced reductions in atherosclerosis occur via smooth muscle cell-specific interaction with PPAR{gamma}.

36

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Pioglitazone decreases plasma angiotensin II concentration in type 2 diabetes

37

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure

38

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats.

39

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Downregulation of peroxisome proliferator-activated receptor-gamma expression in hypertensive atrial fibrillation.

40

1 reference

10.1093/EUROPACE/EUR131

https://api.crossref.org/works/10.1093/EUROPACE/EUR131

1 December 2024

Identifiers

10.1093/EUROPACE/EUR131

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21551479%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84062748&oldid=2282296534"